Cell Cure Neurosciences ^{For Profit}

Cell Cure Neurosciences Ltd. (Cell Cure) is developing cell therapies for retinal and neural degenerative diseases. Its therapeutic programs include OpRegen™ for retinal disease, and the development of neural progenitor cells for degenerative neurological disorders. Cell Cure’s pipeline of regenerative medicine therapies are derived from human embryonic stem cells (hESCs), pluripotent cells which are capable of morphing into all the cell types of the human body. Cell Cure is a majority-owned subsidiary of BioTime, Inc. and is the neurological arm for BioTime’s program for development of human embryonic stem cell-based therapies. Additional shareholders include Teva Pharmaceuticals and Hadasit Bio-Holdings. In October, 2010, Cell Cure entered into an exclusive license option agreement with Teva to develop and commercialize Cell Cure’s OpRegen™ product for the treatment of AMD. Subject to the terms of the agreement, if Teva exercises its option to obtain an exclusive license to OpRegen™, Teva will have responsibility for funding clinical trials from that point on, obtaining regulatory approvals, and marketing the product.